Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2019, Article ID 9627810, 12 pages
https://doi.org/10.1155/2019/9627810
Research Article

Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway

1Biology Department, College of Science, King Khalid University, Abha, Saudi Arabia
2Zoology Department, College of Science, Damanhour University, Egypt
3Department of Basic Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
4King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

Correspondence should be addressed to Attalla Farag El-kott; moc.oohay@fattokle

Received 9 January 2019; Revised 27 April 2019; Accepted 30 April 2019; Published 8 July 2019

Academic Editor: Consuelo Amantini

Copyright © 2019 Attalla Farag El-kott et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Sankaranarayanan and J. Ferlay, “Worldwide burden of gynaecological cancer: the size of the problem,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 20, no. 2, pp. 207–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Bhatla and A. Jones, The World Ovarian Cancer Coalition Atlas, 2018.
  3. G. C. Jayson, E. C. Kohn, H. C. Kitchener, and J. A. Ledermann, “Ovarian cancer,” The Lancet, vol. 384, no. 9951, pp. 1376–1388, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. The Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Gasparri, E. Bardhi, I. Ruscito et al., “PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track?” Geburtshilfe und Frauenheilkunde, vol. 77, no. 10, pp. 1095–1103, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. C. P. Carden, A. Stewart, P. Thavasu et al., “The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer,” Molecular Cancer Therapeutics, vol. 11, no. 7, pp. 1609–1617, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Mabuchi, H. Kuroda, R. Takahashi, and T. Sasano, “The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer,” Gynecologic Oncology, vol. 137, no. 1, pp. 173–179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Janku, T. A. Yap, and F. Meric-Bernstam, “Targeting the PI3K pathway in cancer: are we making headway?” Nature Reviews Clinical Oncology, vol. 15, no. 5, pp. 273–291, 2018. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Nikolopoulos, S. Theocharis, and G. Kouraklis, “Ghrelin: a potential therapeutic target for cancer,” Regulatory Peptides, vol. 163, no. 1-3, pp. 7–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. D. Müller, R. Nogueiras, M. L. Andermann et al., “Ghrelin,” Molecular Metabolism, vol. 4, no. 6, pp. 437–460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Nikolopoulos, S. Theocharis, and G. Kouraklis, “Ghrelin’s role on gastrointestinal tract cancer,” Surgical Oncology, vol. 19, no. 1, pp. e2–e10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Hou, M. S. Kovacs, S. Dhanvantari, and L. G. Luyt, “Development of candidates for positron emission tomography (PET) imaging of ghrelin receptor in disease: design, synthesis, and evaluation of fluorine-bearing quinazolinone derivatives,” Journal of Medicinal Chemistry, vol. 61, no. 3, pp. 1261–1275, 2018. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Waseem, Javaid-ur-Rehman, F. Ahmad, M. Azam, and M. A. Qureshi, “Role of ghrelin axis in colorectal cancer: a novel association,” Peptides, vol. 29, no. 8, pp. 1369–1376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Camina, “Cell biology of the ghrelin receptor,” Journal of Neuroendocrinology, vol. 18, no. 1, pp. 65–76, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. X. Bai, W. P. Wang, P. W. Zhao, and C. B. Li, “Ghrelin attenuates the growth of HO-8910 ovarian cancer cells through the ERK pathway,” Brazilian Journal of Medical and Biological Research, vol. 49, no. 3, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Wang, Q. Chen, G. Li, and D. Ke, “Ghrelin stimulates angiogenesis via GHSR1a-dependent MEK/ERK and PI3K/Akt signal pathways in rat cardiac microvascular endothelial cells,” Peptides, vol. 33, no. 1, pp. 92–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. G.-S. Lien, C.-H. Lin, Y.-L. Yang, M.-S. Wu, and B.-C. Chen, “Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways,” European Journal of Pharmacology, vol. 776, pp. 124–131, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fraser, T. Bai, and B. K. Tsang, “Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function,” International Journal of Cancer, vol. 122, no. 3, pp. 534–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Cassoni, C. Ghé, T. Marrocco et al., “Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines,” European Journal of Endocrinology, vol. 150, no. 2, pp. 173–184, 2004. View at Google Scholar
  21. P. L. Jeffery, A. C. Herington, and L. K. Chopin, “Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines,” Journal of Endocrinology, vol. 172, no. 3, pp. R7–11, 2002. View at Publisher · View at Google Scholar
  22. P. Cassoni, M. Papotti, F. Catapano et al., “Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue,” Journal of Endocrinology, vol. 165, no. 1, pp. 139–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Murata, Y. Okimura, K. Iida et al., “Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells,” Journal of Biological Chemistry, vol. 277, no. 7, pp. 5667–5674, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Aydin, İ. H. Ozercan, F. Dagli et al., “Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland,” Biotechnic & Histochemistry, vol. 80, no. 3-4, pp. 163–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. H. D. Skinner, J. Z. Zheng, J. Fang, F. Agani, and B.-H. Jiang, “Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling,” Journal of Biological Chemistry, vol. 279, no. 44, pp. 45643–45651, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Engelman, “Targeting PI3K signalling in cancer: opportunities, challenges and limitations,” Nature Reviews Cancer, vol. 9, no. 8, pp. 550–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. I. K. Kolasa, A. Rembiszewska, A. Felisiak et al., “PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients,” Cancer Biology & Therapy, vol. 8, no. 1, pp. 21–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. M. Annunziata, H. T. Stavnes, L. Kleinberg et al., “Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer,” Cancer, vol. 116, no. 13, pp. 3276–3284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Lanza Cariccio, D. Scionti, A. Raffa et al., “Treatment of periodontal ligament stem cells with MOR and CBD promotes cell survival and neuronal differentiation via the PI3K/Akt/mTOR pathway,” International Journal of Molecular Sciences, vol. 19, no. 8, p. 2341, 2018. View at Publisher · View at Google Scholar · View at Scopus
  30. H.-G. Wendel, E. . Stanchina, J. S. Fridman et al., “Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy,” Nature, vol. 428, no. 6980, pp. 332–337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Ben-Sahra and B. D. Manning, “mTORC1 signaling and the metabolic control of cell growth,” Current Opinion in Cell Biology, vol. 45, pp. 72–82, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kaimei, H. Cowan Kenneth, and K. Sinha Birandra, “In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts,” Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, vol. 11, no. 3, pp. 153–159, 1999. View at Google Scholar
  33. M. Geretto, A. Pulliero, C. Rosano, D. Zhabayeva, R. Bersimbaev, and A. Izzotti, “Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators,” American Journal of Cancer Research, vol. 7, no. 6, pp. 1350–1371, 2017. View at Google Scholar
  34. D. V. Bulavin, S. Saito, M. C. Hollander et al., “Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation,” The EMBO Journal, vol. 18, no. 23, pp. 6845–6854, 1999. View at Publisher · View at Google Scholar
  35. T. Shono, P. J. Tofilon, T. S. Schaefer, D. Parikh, T. J. Liu, and F. F. Lang, “Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation,” Cancer Research, vol. 62, no. 4, pp. 1069–1076, 2002. View at Google Scholar
  36. M. Jiang, Q. Wei, J. Wang et al., “Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis,” Oncogene, vol. 25, no. 29, pp. 4056–4066, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. T. M. Gottlieb, J. F. M. Leal, R. Seger, Y. Taya, and M. Oren, “Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis,” Oncogene, vol. 21, no. 8, pp. 1299–1303, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Ogawara, S. Kishishita, T. Obata et al., “Akt enhances Mdm2-mediated ubiquitination and degradation of p53,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21843–21850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Wu, G. Yu, T. Yan et al., “Phosphorylation of SET mediates apoptosis via P53 hyperactivation and NM23-H1 nuclear import,” Neurobiology of Aging, vol. 69, pp. 38–47, 2018. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Bhatt, C. Ivan, X. Xie, and Z. H. Siddik, “Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells,” Oncotarget, vol. 8, no. 7, pp. 10905–10918, 2017. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Waseem, M. Duxbury, S. W. Ashley, and M. K. Robinson, “Ghrelin promotes intestinal epithelial cell proliferation through PI3K/Akt pathway and EGFR trans-activation both converging to ERK 1/2 phosphorylation,” Peptides, vol. 52, pp. 113–121, 2014. View at Publisher · View at Google Scholar · View at Scopus